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Background: Pulmonary carcinosarcoma is a biphasic tumour with an unfavourable prognosis. The differential
diagnosis includes pulmonary blastoma and is often challenging.
Case presentation: We here describe a case of blastomatoid pulmonary carcinosarcoma in a 58-year-old patient,
who underwent surgical resection. Histopathological examination revealed immature glandular epithelium
resembling high-grade fetal adenocarcinoma expressing epithelial markers and membranous beta-catenin, and
blastomatoid spindle cells with partial rhabdomyosarcoma-like differentiation. Both elements expressed p53, MDM2,
and cyclin-dependent kinase 4 (CDK4), but not thyroid-transcription factor 1 (TTF-1). Mutation analysis of KRAS, EGFR,
and beta-catenin revealed no mutations. Comparative genomic hybridization detected +1q, +6p, +6q24qter, +8q,
+11q12q14, +11q23qter, +12q12q21, +12q24qter, +17q, +20q, -5q14q23, -9p13pter, -13q21q21, and amplifications
at 12q14q21, 15q24qter, 20q11q12.
Conclusion: The observed molecular and cytogenetic findings may provide additional tools for the differential
diagnosis of biphasic pulmonary neoplasms. Furthermore, TP53, MDM2, CDK4, and PTPN1 may be involved in
tumourigenesis.
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The differential diagnosis of biphasic pulmonary tumours
consisting of a mesenchymal component combined with
adenocarcinoma includes pulmonary blastoma and carci-
nosarcoma [1-3]. The degree and type of differentiation
of both elements, immunohistochemical staining and
molecular genetic findings are of help in establishing the
correct diagnosis, which may be challenging in some
cases. However, the developmental origin and the correct
classification of pulmonary blastoma and carcinosarcoma
is still being discussed on [1]. Here, we describe a case of
pulmonary carcinosarcoma of the blastomatoid variant
in a 58-year-old patient who underwent pneumonec-
tomy. We present the clinico-pathological characteristics
and the results of immunohistochemistry, mutation ana-
lysis, chromogenic in situ hybridization (CISH), and
comparative genomic hybridization (CGH) of this rare* Correspondence: schaeferinga@web.de
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reproduction in any medium, provided the orentity with a review of the literature, providing helpful
diagnostic tools in the differential diagnosis.
Case presentation
A 58-year-old male patient was admitted to hospital
after suffering for several weeks from shoulder pain, dys-
pnoea, and cough. His medical history included chronic
obstructive pulmonary disease and smoking (80 pack
years). Computed tomography (CT) detected a 12.9-cm
sharply marginated mass lesion in the upper right hemi-
thorax with central necroses and marked FDG-glucose
uptake in positron emission tomography with integrated
computed tomography (Figure 1). There was no evi-
dence of distant metastases. Histopathological examin-
ation of a CT-guided biopsy revealed malignant tumour
cells with epithelial and mesenchymal differentiation.
Right-sided pneumectomy with lymphadenectomy was
performed, rendering a well circumscribed tumour of
15 x 9 x 6 cm size with a soft fleshy, tan-white, lobulated
cut surface. Chest wall or pleura were not infiltrated.
Microscopically, the lesion was composed of areas of
glandular differentiation and immature spindle cell areasl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Radiographic findings of the blastomatoid pulmonary
carcinosarcoma. Preoperative computed tomography (CT) detected
a sharply marginated tumour in the upper right hemithorax of up to
12.9 cm size (A, coronal view). The tumour extended to the right
hilus, pleura, and the spinal column. Positron emission tomography
with integrated computed tomography (FDG-PET/CT, Philips Gemini,
PET-acquisition 90 minutes after intravenous injection of 198
megabecquerel 2-(18F)-fluoro-2-deoxy-D-glucose) revealed marked
FDG-glucose uptake in the pulmonary mass, especially median,
lateral and caudal, with a maximum standardized uptake value
(SUVmax) of 14.1 (B, fusion PET/CT, coronal view).
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The tumour exhibited numerous atypical mitotic figures,
rich vascularization, and regressive changes including
calcifications and extensive necroses. The epithelial com-
ponent, accounting for ~40% of the vital tumour, showed
primitive differentiation, in some areas with nuclear aty-
pia and a branching (immature) architecture of glands
composed of columnar cells with palisading elliptic nu-
clei with subnuclear vacuoles suggestive of high-grade
fetal adenocarcinoma.
Immunohistochemically, the glandular structures expressed
epithelial markers including epithelial membrane anti-
gen (EMA; Dako, Glostrup, Denmark), pan-cytokeratin
(Dako), carcinoembryonic antigen (CEA; Zytomed Sys-
tems, Berlin, Germany), CK7 (Dako), and focal p63
(BioGenex, San Ramon, CA). Thyroid transcription fac-
tor 1 (TTF-1; Dako) was not expressed. Staining for
beta-catenin (Medac, Wedel, Germany) demonstrated a
membranous expression in the epithelial structures.
The spindle cell component expressed vimentin (Dako),
desmin (Invitrogen, Camarillo, CA) in 10% of tumour
cells, and myogenin (Dako) in 10% of tumour cells indi-
cating partial rhabdomyosarcoma-like differentiation,
EGFR (Invitrogen), and CD56 (Invitrogen). Both com-
ponents expressed p53 (Dako), MDM2 (Zytomed Sys-
tems), and cyclin-dependent kinase 4 (CDK4; Zytomed
Systems). Proliferative activity was assessed by Ki67
(Zytomed Systems) immunostaining and was estimated
at 60%.
A SYT-SSX fusion gene suggestive of synovial sarcoma
was not detected by RT-PCR. Sequencing analysis of
KRAS exon 1 and 2, EGFR exon 19, 20, and 21, and
beta-catenin exon 3 showed no mutations. CGH analysiswas performed as described previously [4] and revealed
chromosomal gains at 1q, 6p, 6q24qter, 8q, 11q12q14,
11q23qter, 12q12q21, 12q24qter, 17q, 20q, losses at
5q14q23, 9p13pter, 13q21q21, and amplifications at
12q14q21, 15q24qter, 20q11q12 (Figure 3). CISH ana-
lysis verified an amplification of MDM2.
The diagnosis of the blastomatoid variant of pulmon-
ary carcinosarcoma was established and the tumour was
finally staged at pT3, pN0 (0/15), pMX, G3, R0, UICC
stage 2b. The patient recovered well and was discharged
21 days after surgery. An optional adjuvant therapy was
discussed with the patient, but he refused. Currently the
patient is doing well and there is no evidence of tumour
relapse 30 months after the resection.
The differential diagnoses of biphasic pleuropulmon-
ary tumours in adults include glandular malignant per-
ipheral nerve sheath tumour (MPNST), synovial
sarcoma, and malignant mesothelioma [2,3,5]. When
only small biopsy specimen are available and both com-
ponents are not represented, carcinosarcoma may also
be misinterpreted as an either entirely epithelial or mes-
enchymal neoplasm [2]. In glandular MPNST, rhabdo-
myosarcomatous elements may be present, but the
tumour usually displays intestinal type-epithelium with
goblet cells. Furthermore, the sarcomatoid part of
MPNST expresses S100 protein and vimentin, and the
tumour is associated with neurofibromatosis type 1 [6].
Synovial sarcoma was ruled out because the characteris-
tic SYT-SSX fusion gene was not detected [7]. Malignant
mesothelioma was also ruled out by negative staining for
mesothelial markers (i. e. calretinin, D2-40).
Furthermore, pulmonary blastoma should be consid-
ered in the differential diagnosis if the epithelial compo-
nent consists of adenocarcinoma [2]. As reported in the
literature, biphasic pulmonary blastoma and carcinosar-
coma, in particular the blastomatoid variant of the latter,
may share common features, making a differentiation
between both entities difficult [1,2,8]. Table 1 sum-
marizes the clinicopathologic characteristics of pulmon-
ary carcinosarcoma, pulmonary blastoma, and the
present case. The blastomatoid variant of carcinosar-
coma is not yet recognized as a distinct entity by the
WHO classification of tumours [3]. In contrast to con-
ventional pulmonary carcinosarcoma, which contains
squamous cell carcinoma, adenocarcinoma, adenosqua-
mous carcinoma, or large cell carcinoma as epithelial
component, the blastomatoid variant of carcinosarcoma
comprises high-grade adenocarcinoma of the fetal lung
type/clear cell adenocarcinoma with fetal lung features
[1]. This is a typical feature of pulmonary blastoma and
therefore led to the designation as “blastomatoid pul-
monary carcinosarcoma” [1].
In the case presented here, the gross appearance
and localization of the tumour were not helpful in
Figure 2 Microscopic findings of the blastomatoid pulmonary carcinosarcoma. On microscopic view, the blastomatoid pulmonary
carcinosarcoma displayed a biphasic growth pattern (A, haematoxylin-eosin (HE), x 20). The epithelial elements showed glandular differentiation
(B, x 100) and displayed focal cellular atypia and mitotic figures (B, inset) resembling high-grade fetal adenocarcinoma. These structures were
surrounded by malignant, blastomatoid spindle cells (C, x 200), which showed partial rhabdomyosarcomatous differentiation with
rhabdomyoblasts (C, inset, desmin). Immunohistochemical staining with pan-cytokeratin (D) was positive in the carcinomatous areas. Both
components did not express thyroid transcription factor 1 (TTF-1; E). Membranous beta-catenin (F) expression was detected in the epithelial
structures; MDM2 (G) and cyclin-dependent kinase 4 (CDK4; H) were expressed in both components (x 200).
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Figure 3 Results of comparative genomic hybridization (CGH). CGH of the blastomatoid pulmonary carcinosarcoma revealed ish cgh enh(1)
(q),dim(5)(q14q23),enh (6)(p),enh(6)(q24qter),enh(8)(q),dim(9)(p13pter),enh(11)(q12q14),enh(11)(q23qter),enh(12)(q12q21),amp(12)(q14q21),enh(12)
(q24qter),dim(13)(q21q21),amp(15)(q24qter),enh(17)(q),enh(20)(q),amp(20)(q11q12). The number of chromosomes included in the CGH analysis is
indicated at the bottom of each individual profile.
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toma and carcinosarcoma are known to arise either
central/peribronchial or in the periphery of the lung,
forming a large bulk [2,8]. Pulmonary carcinosarcoma
is reported to arise in elderly men between 50–80 years
who are heavy smokers, as our patient [1,2,8,9],
whereas the mean age of patients with pulmonary blas-
toma is around 35–50 years [2,10,11]. On microscopic
examination, undifferentiated adenocarcinoma, inter-
mixed rhabdomyosarcoma-like spindle cells, and exten-
sive necroses may be observed in both entities [2,8].
It has been proposed to classify pulmonary blastoma
into three groups: biphasic pulmonary blastoma, well-
differentiated fetal adenocarcinoma, and pleuropulmon-
ary blastoma, the latter arising only in children [10].
Biphasic pulmonary blastoma enters the differential
diagnosis of carcinosarcoma as it combines malignant
epithelial and mesenchymal components [10].
The epithelial component in the present case showed
focal cellular atypia, mitotic figures, and branching
glands composed of columnar cells with palisading el-
liptic nuclei with subnuclear vacuoles resembling high-
grade fetal adenocarcinoma as described for carcino-
sarcoma [1]. In contrast, well-differentiated or low-grade
adenocarcinoma would be a typical feature of pulmonary
blastoma [1]. Morules, as described to occur in 43% of
biphasic pulmonary blastomas, were not present [2,11].
The mesenchymal component displayed a rather imma-
ture, blastoma-like differentiation. Expression of TTF-1
occuring rather in the well differentiated fetal adenocar-
cinoma of pulmonary blastoma, was not observed in thepresent case, favouring the diagnosis of carcinosarcoma
[9]. Furthermore, it has been demonstrated that low-
grade adenocarcinoma of the fetal lung type/well-differ-
entiated fetal adenocarcinoma constantly shows aberrant
nuclear or cytoplasmic localization of beta-catenin,
whereas high-grade adenocarcinoma of the fetal lung
type/clear cell adenocarcinoma with fetal lung features
shows the same membranous localization of beta-catenin
as conventional pulmonary adenocarcinomas, which
could also be observed in the present case [1].
Previous immunohistochemical and molecular ana-
lyses in pulmonary carcinosarcoma revealed mutations
of TP53, but not of KRAS or beta-catenin [1,2]. To our
knowledge, mutations of EGFR, MDM2 or CDK4 have
not yet been investigated in this entity. Cytogenetic aber-
rations reported for this entity include allelic gains at 1q,
3q, 5p, 8q, 12p, and losses at 3q, 5q, 17p [2]. Pulmonary
blastoma on the other hand is characterized by TP53,
MDM2, and beta-catenin mutations, whereas EGFR and
KRAS mutations are usually not detected [1,10,12,13].
Furthermore, trisomies 2 and 8, and allelic imbalances at
14q24q32 and 17p11p13 are reported for this tumour
entity [2,10,12].
Immunohistochemically, an expression of p53 was
detected in the present case consistent with an under-
lying TP53 mutation, but no EGFR, KRAS or beta-
catenin mutation were found. Additionally, we observed
a high number of chromosomal aberrations by CGH
including gains at 1q, 6p, 6q24qter, 8q, 11q12q14,
11q23qter, 12q12q21, 12q24qter, 17q, 20q, losses at
5q14q23, 9p13pter, 13q21q21, and amplifications at
Table 1 The clinicopathologic and molecular genetic characteristics of pulmonary blastoma, pulmonary carcinosarcoma, and the present case




































































































































































EMA: epithelial membrane antigen.
CK: cytokeratin.
CEA: carcinoembryonic antigen.
TTF-1: thyroid transcription factor 1.
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served gains at 1q, 8q, and losses at 5q are among the
aberrations described for pulmonary carcinosarcoma [2].
The present case, however, displayed several more imbal-
ances that have not yet been described for pulmonary
carcinosarcoma. The high number of chromosomal
imbalances indicates a high degree of chromosomal in-
stability and tumour progression in the blastomatoid
variant of carcinosarcoma. Furthermore, the observed
imbalances may be of help in the differential diagnosis,
in particular if +1q, +8q, and -5q are detected. The devel-
opmental origin of both tumour components is unclear
and an origin from two or more stem cells (multiclonal
hypothesis) or an origin from a single totipotential stem
cell that differentiates into separate epithelial and mes-
enchymal directions (monoclonal hypothesis) seems
possible [14]. Previous analyses in pulmonary carcino-
sarcoma [15], biphasic pulmonary blastoma [12], and
carcinosarcomas of other localizations [14] provide evi-
dence that the epithelial and mesenchymal component
of these biphasic tumours harbour a different morph-
ology, but are monoclonal in origin.
The observed chromosomal changes may give insight
into tumourigenesis and help to identify possible can-
didate genes. The amplicon 12q13q21 (including the
observed 12q14q21) is also typically detected in differ-
ent types of sarcoma, particularly in liposarcoma and
osteosarcoma [16]. It harbors several genes, of which
the amplifications or mutations of MDM2 and CDK4
were confirmed immunohistochemically and by CISH
analysis in the present case and may play a role in
tumourigenesis [10,16]. Over-expression of MDM2 has
previously been observed in 83% of biphasic pulmon-
ary blastomas, but it has so far not been studied in
pulmonary carcinosarcomas [10]. Furthermore, the
observed amplicon at 15q24qter has also been reported
in small-cell lung cancers, while the amplicon detected
here at 20q11q12 includes the PTPN1 gene located at
20q12 which serves as a non-receptor tyrosine phos-
phatase involved in growth regulation [16]. It has been
found to be over-expressed in 72% of breast carcin-
omas [16].
As reported, complete surgical resection is the treat-
ment of choice in patients with resectable tumours [2].
Chemotherapy and radiation can be used in an adjuvant
setting although specific regimens do not exist [2,3]. In
the present case, the mesenchymal component slightly
predominated and an adjuvant therapy according to
guidelines for soft tissue sarcomas was discussed. How-
ever, since complete resection was achieved, lymph node
or distant metastases were ruled out, and the patient
refused, no adjuvant therapy was applied.
The present case illustrates the diagnostic difficulties in
differentiating pulmonary carcinosarcoma from biphasicpulmonary blastoma, in particular if the carcinosar-
coma contains fetal adenocarcinoma and a blasto-
matoid mesenchymal component. It also highlights the
usefulness of additional molecular and genomic ana-
lyses. From our findings we conclude that similar to
pulmonary blastoma pulmonary carcinosarcoma may
harbour MDM2 and lack EGFR mutations. Therefore,
presence of TP53, MDM2, and lack of KRAS and
EGFR mutations may not be helpful in the differential
diagnosis of both entities. Only the presence or ab-
sence of beta-catenin mutations will serve as a useful
diagnostic tool in certain cases. In the present case,
the diagnosis was discussed with reference pathologists
who favoured the diagnoses of either pulmonary blas-
toma or blastomatoid carcinosarcoma. Although high-
grade fetal adenocarcinoma was not present in every
tumour sample, the diagnosis of pulmonary carcinosar-
coma was finally made based on the mutation ana-
lyses, particularly of beta-catenin.
Conclusions
In conclusion, the presence of high-grade fetal adenocar-
cinoma without TTF-1 expression, lack of beta-catenin
mutation, and detection of 1q, +8q, and -5q by CGH in
a biphasic lung tumour in adult patients favours the
diagnosis of pulmonary carcinosarcoma. Furthermore,
mutations of TP53, MDM2, CDK4, and PTPN1 may play
a role in development and progression of this tumour
entity.
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